within Pharmacolibrary.Drugs.ATC.L;

model L01FG01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0038333333333333336,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.00328,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby preventing the growth of blood vessels that supply tumors. It is used as an anti-angiogenic therapy for a variety of cancers, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and glioblastoma. Bevacizumab is approved and marketed under the brand name Avastin.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters refer to adult cancer patients receiving bevacizumab by intravenous infusion in multiple clinical studies. PK shows linear kinetics and minimal accumulation. Parameters listed are typical for a two-compartment model.</p><h4>References</h4><ol><li><p>Dupuis-Girod, S, et al., &amp; Chinet, T (2023). Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial. <i>Journal of internal medicine</i> 294(6) 761–774. DOI:<a href=&quot;https://doi.org/10.1111/joim.13714&quot;>10.1111/joim.13714</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37592715/&quot;>https://pubmed.ncbi.nlm.nih.gov/37592715</a></p></li><li><p>Han, K, et al., &amp; Jin, J (2016). Population pharmacokinetics of bevacizumab in cancer patients with external validation. <i>Cancer chemotherapy and pharmacology</i> 78(2) 341–351. DOI:<a href=&quot;https://doi.org/10.1007/s00280-016-3079-6&quot;>10.1007/s00280-016-3079-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27329360/&quot;>https://pubmed.ncbi.nlm.nih.gov/27329360</a></p></li><li><p>Rietveld, PCS, et al., &amp; Koolen, SLW (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 176 116820–None. DOI:<a href=&quot;https://doi.org/10.1016/j.biopha.2024.116820&quot;>10.1016/j.biopha.2024.116820</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38810398/&quot;>https://pubmed.ncbi.nlm.nih.gov/38810398</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FG01;
